JO
Therapeutic Areas
Acrivon Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ACR-368 (Prexasertib) | Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Urothelial Carcinoma | Phase 2 |
| ACR-2316 | Advanced Solid Tumors | Phase 1 |
| ACR-6840 | Undisclosed Solid Tumors | Preclinical |
Leadership Team at Acrivon Therapeutics
PB
Peter Blume-Jensen
CEO, President, Founder, Chairperson
EG
Erick Gamelin
Chief Development Officer
KM
Kristina Masson
Co-Founder, EVP, Business Operations, Site Head, Director
ED
Eric Devroe
Chief Operating Officer
MS
Michail Shipitsin
Head of Biomarker Development
JJ
Joon Jung
Head of Data Science
JV
John van Duzer
Head of Chemistry Manufacturing and Controls
TP
Thomas P. Nifong
Head of Clinical CDx Operations
SR
Sam Rua
Head of CDx Regulatory
MM
Mary-Alice Miller
Chief Legal Officer